Italiano | English
Recording of the general session presentations is now available. To watch the video visit the web site:
look at the backstage: http://youtu.be/diJdgiWduj8
Continuing the tradition of past years, on Friday, April 4th, 2014 we will host the 4th Patients' Day dedicated to subjects with one of the Philadelphia-chromosome negative myeloproliferative neoplasms (MPN), in conjunction with the 4th annual Florence-Miami Patient Conference, that will be held on April 12th in Miami.
For more information and for registrations, visit the web site: http://www.mpn-florence.com/2014/?lng=en
On the website of the congress (http://www.mpn-florence.com/2013/index.php ) are now available the videos of the talks in the morning, and presentations of all the speakers.
On May 16, 2013 the site visit of the AGIMM project was held in Florence. Three foreign auditors, highly-qualified scientists from Europe and the United States with extensive experience in the field of oncology and blood diseases, and two members of the Scientific Direction of AIRC, sit down together for a whole day with the scientists of the AGIMM project with the aim to evaluate the work performed in the first three years thanks to the funds from the "5 per Mille" AIRC grant. The reviewers assessed that the results obtained so far, both in basic/translational science and in clinical research, were important and suggested that research would deserve to be further supported for at least the next two years. We are all very proud of this accomplishment, and would like to extend our gratitude to the reviewers and members of AIRC for their dedication to the scientific evaluation, to AIRC for the invaluable support, that above all allows young scientists and doctors to perform research, and to all patients whose enthusiasm in participating to the studies and donating precious biologic material has been key to success of the entire project.
The Cyto-PV study was presented on Sunday, December 9th, at the meeting of the American Society of Hematology in Atlanta and published simultaneously in the New England Journal of Medicine. It is an independent study, with principal investigator prof. Tiziano Barbui of Bergamo Hospital and coordinator Dr. Roberto Marchioli of the Institute Mario Negri-Sud, funded by the Italian Agenzia Italiana per il Farmaco (AIFA) and by AIRC, AGIMM group financed with funds from the "5 per mille". Twenty-six italian haematological centers including the centers of the project AGIMM contributed to the study. The study was conducted in 365 patients with polycythemia vera, a myeloid malignancy characterized by a genetic mutation of JAK2 and by increase of blood cells, particularly red blood cells, with a high risk of arterial and venous thrombosis and, less commonly, of leukemic transformation. The aim of the study was to show what was the best value of hematocrit (which correlates with the number of red blood cells) for the prevention of thrombosis without increasing the risk of leukemic transformation due to excess treatment in patients receiving chemotherapy, even in association with phlebotomies. The study demonstrated that an hematocrit value of less than or equal to 0.45 allows to reduce by about 4 times the frequency of thrombosis compared to patients with hematocrit maintained up to 0.50 without an increase of leukemic transformation. The results of this research will then have an immediate and profound effect on the therapeutic management of patients with polycythemia vera.
The paper is published online
The first spontaneous clinical trial of the AGIMM group has been activated, with the aim to study the effects of the JAK1/2 inhibitor Ruxolitinib in patients with splanchnic thrombosis associated with myeloproliferative disease. To know the participating centers, please refer to the "Active Trials" section of this site.
Now added in the Link page of the AGIMM web site, section Links of interest about Ph-negative Myeloproliferative Neoplasms
Continuing the tradition of past years, on Friday, March 15, 2013 we will host the 3rd Patients' Day dedicated to subjects with one of the Philadelphia-chromosome negative myeloproliferative neoplasms (MPN). For more information and for registrations, visit the web site: http://www.mpn-florence.com/2013/?lng=en
We are pleased to announce the "3rd Annual Florence Meeting on Myeloproliferative Neoplasms" which will be held on Saturday, March 16, 2013. This educational and research symposium is held in conjunction with the "Annual Meeting of the International Working Group for MPN Research and Treatment (IWG-MRT)", which will be held on Sunday, March 17, 2013. For more information, visit the web site: http://www.mpn-florence.com/2013/?lng=en
The JAK1 and JAK2 inhibitor Ruxolitinib was approved in November 2011 by the FDA (Food and Drug Administration), the U.S. government agency that deals with the regulation of food and pharmaceuticals. The approval covers only the United States, but it may represent the first step for a rapid approval in Europe. Ruxolitinib is the first drug approved by FDA for patients with myelofibrosis, both primary myelofibrosis and myelofibrosis secondary to polycythemia vera and essential thrombocythemia, who are classified as intermediate or high risk disease. Efficacy data on which the FDA based the approval were provided from the phase III studies COMFORT-I and COMFORT-II, which demonstrated the superiority of the drug compared to placebo (inactive control powder) or conventional therapy, respectively, in reducing the volume of the spleen and the symptoms associated with the disease, overall improving the quality of life of patients. For more information, visit the web site: http://www.fda.gov/
We are pleased to announce the "2nd Annual Florence Meeting on Myeloproliferative Neoplasms" which will be held on Saturday, April 21, 2012. This educational and research symposium is held in conjunction with the "Annual Meeting of the International Working Group for MPN Research and Treatment (IWG-MRT)", which will be held on Sunday, April 22, 2011. As for previous year, on Friday, April 20, we will host the 2nd Patients' Day dedicated to subjects with one of the Philadelphia-chromosome negative myeloproliferative neoplasms (MPN). For more information, visit the web site: http://www.mpn-florence.com/2012/en/
On June 4th, 2011, at the annual meeting of the American Society of Clinical Oncology in Chicago, were announced via press release the results of the phase III trials with the JAK2 inhibitor INC424, also called Ruxolitinib, in primary myelofibrosis and myelofibrosis secondary to polycythemia vera and essential thrombocythemia. The trials have shown superiority of this drug in reducing the plenomegaly and in improving the systemic symptoms of the disease, compared to conventional therapy. Prof. Vannucchi, University of Florence, attended at the press release, and presented the scientific communication at the plenary session of the meeting.
These two events organized for the first time in Florence on April, 16th and 15th 2011 have been a huge success, that allow to repeat the event in subsequent years. On the web site http://www.mpn-florence.com/2011/it/ is possible to find the speakers' presentations, photos and video of the "Patient's day", as well as updates on events of the following year.
At the conclusion of the first year of the research project funded by the AIRC Molecular and Clinical Oncology "5 per mille" project, and following the suggestion of AIRC scientific direction, a committee of international scientists, experts in the field of chronic myeloproliferative neoplasms, will be called to evaluate and discuss the results obtained so far. This "External Advisory Board", which is composed of Dr Ron Hoffman, Mount Sinai Hospital, New York, USA, leader of the MPD-RC (myeloproliferative Disorders Research Consortium), Dr Nick Cross, Wessex General Hospital, Salisbury, UK, Director Laboratory of Molecular Biology and chair of a major research project on myeloproliferative neoplasms in England and Dr. William Vainchenker, Gustave Roussy Institute, University of Paris 3, Paris, France, who discovered the JAK2V617F mutation in myeloproliferative neoplasms, will meet Saturday, October 29, 2011. The purpose of the meeting is to obtain an assessment of the work, suggestions and new ideas from international experts outside the project through discussion with the PIs of the different units involved.
These two events, the first dedicated to all physicians interested in getting updated on recent advances in laboratory and clinical research in MPN, and the second for patients who wish to receive and request information from experts in the fields of MPN, will be held in Florence on 16 and 15 April 2011, respectively. Please note that only registered and confirmed participant will be admitted to the meeting. For more information, visit: http://www.mpn-florence.com/it/index.php
In recent years the most important data in genomic research have focused on the DNA polymorphisms, which have contributed to the knowledge of variations in the genome and their correlation with clinical and phenotypic data. Next-generation sequencing platforms are already available, and the Interdepartmental Centre for Genomics Research of University of Modena is one of the Italian centers to have this technology. Rationale of the meeting is submit to physicians and researchers in the biomedical area the diagnostic applications of new technology of massively parallel DNA sequencing (brochure - 950 kB ). For more information, visit web site: http://www.ngsday2011.unimore.it/ .
A new clinical trial with the JAK2 inhibitor "INC424" will be activated soon for patients with Polycythemia Vera resistant or intolerant to hydroxyurea. Patients enrolled in this new trial called "RESPONSE" (Randomized, open label, multi center phase III of Efficacy and Safety in POlicythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK2 iNhibitor INC424 tablets verSus bEst available care) will be randomized between the INC424 treatment arm and the best available therapy arm, with the possibility to get the experimental drug if randomized to the "best available treatment" group in case of lack of satisfactory control of the disease after 8 months from the beginning of the study. INC424 is an inhibitor of JAK1 and JAK2 already employed in Myelofibrosis, Polycythemia Vera and Essential Thrombocythemia, with good results in controlling hematocrit, platelets, splenomegaly and systemic symptoms with a high tolerance. The protocol "RESPONSE" will be activated at the AGIMM centers of Bergamo, Florence, Pavia and Turin.
On Saturday, April 16th 2011, will be held in the prestigious Salone de' Dugento in Palazzo Vecchio, Florence, the "1st Annual Florence Meeting on Myeloproliferative Neoplasms & the Annual IWG-MRT Workshop". Until now this event, which gets together the best national and international experts on these hematologic diseases , has taken place in Houston . This educational and research symposium is held in conjunction with the Annual International Working Group for MPN Research and Treatment (IWG-MRT), which will be held on Sunday, April 17, 2011. The invitation to attend the Saturday meeting is open to all who are interested in getting updated on recent advances in laboratory and clinical research in MPN, up to 120 participants. The Sunday meeting is restricted to IWG-MRT members and will focus on new collaborative projects. For more information, visit the web site: http://www.mpn-florence.com/en/index.php
Sunday, November 7th at 9.30 pm, will be broadcast on RAI-3 a special episode of Elisir, the health program conducted by Michele Mirabella, dedicated to the Day for cancer research organized by AIRC. Among the guests, will be present in the study Prof. Alessandro Vannucchi, University of Florence, who will discuss research on various types of leukemia. More information.
During the Day for Research on Cancer organized by AIRC, are set for Saturday, November 6th, 2010, the "Meetings open to the public with the research", where scientists and personalities from the world of art will be available for a comparison with the participants , students and AIRC supporters who are interested in participating. In Florence, will be attended by professors Alessandro M. Vannucchi, coordinator of the AGIMM group, Santarpia Libero and Paola Romagnani for Research, and the sculptor Fabrizio Corneli for the Art. The meeting will be based at the Auditorium complesso si Sant'Apollonia, via San Gallo 25 (poster - 250 kB ). For more information, visit AIRC web site: http://www.airc.it/giornata-ricerca-cancro/incontri.asp .
The 1th Annual Florence Meeting on Myeloproliferative Neoplasms of the IWG-MRT (International Working group for Myelofibrosis Research and Treatment) will take place in Florence on April 15, 2011. This annual meeting, traditionally organized by Mayo Clinic (Rochester) and MD Anderson Cancer Centre in Houston, for the first time will cross the Atlantic and move to an European city! The meeting is open to basic and clinical researchers in Ph negative chronic myeloproliferative neoplasms. Admission is free, up to 100 participants. Detailed information about program, registration, location and accommodation will follow soon.
On September 8, at 1.00 pm, Dr. Robert Kralovics, from Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna, will hold a seminar focused on mechanisms of new somatic mutations in patients with chronic myeloproliferative neoplasms. The seminar, organized by Prof. Alessandro M. Vannucchi and prof. Lucio Luzzatto, director of Istituto Toscano Tumori, will be held in the University of Florence. Location is hall A, Pharmacology Department, viale Pieraccini 6, Florence. Download brochure ( PDF file, 320 kB)
The next edition of this meeting organized by the European School of Hematology will be held in Albufeira, Portugal, from Septembre 30th to October 3rd . It will be a forum for discussing about recent insights in molecular pathogenesis and therapy of chronic myeloproliferative neoplasms, bringing together clinicians and scientists with interest in these disorders. Topics will range from genomics to murine models, prognostic factors, clinical trials with novel drugs. The agenda includes more than 30 oral presentations and a poster session. (for further information )
PDF files can be viewed with Adobe Reader. You may download it from: http://get.adobe.com/uk/reader/